KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cost of Revenue: 2016-2024

Historic Cost of Revenue for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Dec 2024 value amounting to $81.8 million.

  • Acadia Pharmaceuticals' Cost of Revenue rose 14.80% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.6 million, marking a year-over-year increase of 8.53%. This contributed to the annual value of $81.8 million for FY2024, which is 96.55% up from last year.
  • Acadia Pharmaceuticals' Cost of Revenue amounted to $81.8 million in FY2024, which was up 96.55% from $41.6 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Cost of Revenue high stood at $81.8 million for FY2024, and its period low was $10.2 million during FY2022.
  • Moreover, its 3-year median value for Cost of Revenue was $41.6 million (2023), whereas its average is $44.5 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Cost of Revenue crashed by 46.89% in 2022 and then spiked by 309.58% in 2023.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Cost of Revenue stood at $10.2 million in 2020, then skyrocketed by 87.45% to $19.1 million in 2021, then plummeted by 46.89% to $10.2 million in 2022, then spiked by 309.58% to $41.6 million in 2023, then surged by 96.55% to $81.8 million in 2024.